

07-09-04

IFW

PTO/SB/21 (08-00)

Please type a plus sign (+) inside this box → ☒


Approved for use through 10/31/2002. OMB 0651-0031


U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM JUL 08 2004 (to be used for all correspondence after initial filing)	Application Number	10/659,578
	Filing Date	September 10, 2003
	First Named Inventor	Zsuzanna Nagy
	Group Art Unit	1645
	Examiner Name	Not Yet Known
Total Number of Pages in This Submission		Attorney Docket Number 43962-010810

ENCLOSURES (check all that apply)				
<input checked="" type="checkbox"/> Fee Transmittal Form <input checked="" type="checkbox"/> Fee Attached (PTO DEPOSIT ACCOUNT) <input type="checkbox"/> Amendment <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Assignment Papers (for an Application) <input type="checkbox"/> Substitute Drawing (Figure 1) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Combined Declaration and New Power of Attorney (9 pages) <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> Diskette; Number of diskettes:	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Form 1449; Copies of References C1-C22; and Post-Card		
<table border="1"> <tr> <td>Remarks</td> <td></td> </tr> </table>			Remarks	
Remarks				

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	James F. Ewing – Reg. No.: 52,875 Greenberg Traurig, LLP
Signature	
Date	July 8, 2004

CERTIFICATE OF EXPRESS MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as Express Mail Mailing Label No.: EV426280533US in an envelope addressed to: Mail Stop Amendment – Commissioner for Patents, Post Office Box 1450, Alexandria, VA 22313-1450 on July 8, 2004.			
Typed or printed name	Anne-Marie Keefe		
Signature		Date	July 8, 2004

Burden Hour Statement. This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231.
143488v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

**FEE TRANSMITTAL
for FY 2003**

JUL 08 2004

Patent fees are subject to annual revision.

TOTAL AMOUNT OF PAYMENT (\$) 180

Complete if Known

Application Number 10/659,578

Filing Date September 10, 2003

First Named Inventor Zsuzanna Nagy

Examiner Name Not Yet Known

Group / Art Unit 1645

Attorney Docket No. 43962-010810

METHOD OF PAYMENT (check one)

- 1.
- ☒
- The Commissioner is hereby authorized to charge indicated fees and credit any over payments to:

Deposit Account Number 50-2678

Deposit Account Name Greenberg Traurig, LLP

- ☒
- Charge Any Additional Fee Required Under 37 CFR 1.16 and 1.17
-
- ☒
- Applicant claims small entity status. See 37 CFR 1.27

- 2.
- ☐
- Payment Enclosed:

☐ Check ☐ Credit card ☐ Money ☐ Other Order**FEE CALCULATION****1. BASIC FILING FEE**

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1001	750	2001	375	Utility filing fee	
1002	330	2002	165	Design filing fee	
1003	520	2003	260	Plant filing fee	
1004	750	2004	375	Reissue filing fee	
1005	160	205	80	Provisional filing fee	

SUBTOTAL (1)

(\$) 0

2. EXTRA CLAIM FEES

			Extra Claims		Fee from below		Fee Paid
Total Claims	<input type="text"/>	-20 **	=	<input type="text" value="0"/>	X	<input type="text"/>	= <input type="text" value="0"/>
Independent Claims	<input type="text"/>	-3 **	=	<input type="text" value="0"/>	X	<input type="text"/>	= <input type="text" value="0"/>
Multiple Dependent					X	<input type="text"/>	= <input type="text" value="0"/>

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description
1202	18	2202	9	Claims in excess of 20
1201	84	2201	42	Independent claims in excess of 3
1203	280	2203	140	Multiple dependent claim, if not paid
1204	84	2204	42	** Reissue independent claims over original patent
1205	18	2205	9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2)

(\$) 0

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)**3. ADDITIONAL FEES**

Large Entity Fee Code	Large Entity Fee (\$)	Small Entity Fee Code	Small Entity Fee (\$)	Fee Description	Fee Paid
1051	130	2051	65	Surcharge - late filing fee or oath	
1052	50	2052	25	Surcharge - late provisional filing fee or cover sheet.	
1053	130	1053	130	Non-English specification	
1812	2,520	1812	2,520	For filing a request for reexamination	
1804	920*	1804	920*	Requesting publication of SIR prior to Examiner action	
1805	1,840*	1805	1,840*	Requesting publication of SIR after Examiner action	
1251	110	2251	55	Extension for reply within first month	
1252	410	2252	205	Extension for reply within second month	
1253	930	2253	465	Extension for reply within third month	
1254	1,450	2254	725	Extension for reply within fourth month	
1255	1,970	2255	985	Extension for reply within fifth month	
1401	320	2401	160	Notice of Appeal	
1402	320	2402	160	Filing a brief in support of an appeal	
1403	280	2403	140	Request for oral hearing	
1451	1,510	1451	1,510	Petition to institute a public use proceeding	
1452	110	2452	55	Petition to revive - unavoidable	
1453	1,300	2453	650	Petition to revive - unintentional	
1501	1,300	2501	650	Utility issue fee (or reissue)	
1502	470	2502	235	Design issue fee	
1503	630	2503	315	Plant issue fee	
1460	130	1460	130	Petitions to the Commissioner	
1807	50	1807	50	Processing fee under 37 CFR 1.17 (q)	
1806	180	1806	180	Submission of Information Disclosure Stmt	180.00
8021	40	8021	40	Recording each patent assignment per property (times number of properties)	
1809	750	2809	375	Filing a submission after final rejection (37 CFR § 1.129(a))	
1810	750	2810	375	For each additional invention to be examined (37 CFR § 1.129(b))	
1801	750	2801	375	Request for Continued Examination (RCE)	
1802	900	1802	900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3)

(\$) 180

SUBMITTED BY**Complete (if applicable)**

Name (Print/Type) James E. Ewing

Registration No. Attorney/Agent

52,875

Telephone

617-310-6000


Signature

Date

July 8, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



PATENT
Atty. Docket No. 43962-010810

THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Zsuzanna Nagy
SERIAL NO.: 10/659,578 GROUP NO.: 1645
FILING DATE: September 10, 2003 EXAMINER: Not Yet Assigned
TITLE: Diagnostic Screens for Alzheimer's Disease

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents C1-C22 are enclosed.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

☐ (1) within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the first Office action on the merits, or before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. 1.114; or

☒ (2) after the period defined in (1) but before the mailing date of a final action or a notice of allowance under 37 C.F.R. 1.311, and

☐ the requisite Statement is below, **OR**

☒ the requisite fee under 37 C.F.R. 1.17(p), namely \$180.00, is included herein, **or**

☐ (3) after the mailing date of a final action or notice of allowance but before the payment of

the issue fee, AND

☐ the requisite Statement is below, **OR**

☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely \$180.00 is included herein.

A copy of each of the above-identified information is enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.


Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. The Commissioner is authorized to charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-2678, Reference No. 43962-010810.

Date: July 8, 2004

Tel. No.: (617) 310-6000
Fax No.: (617) 310-6001


143457v1

Respectfully submitted,



James F. Ewing
Attorney for Applicant(s)
Registration No.: 52,875
Greenberg Traurig, LLP
One International Place
Boston, Massachusetts 02110

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00, OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/659,578
	Filing Date	September 10, 2003
	First Named Inventor	Nagy
	Group Art Unit	
	Examiner Name	Not Yet Assigned
	Attorney Docket Number	43962-010810

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation	
						Yes	No

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C1	Arendt T, Holzer M and Gärtner U, "Neuronal expression of cycline dependent kinase inhibitors of the INK4 family in Alzheimer's disease," <u>J Neural Transm</u> , 105: 949-960 (1998)
	C2	Arendt T, Rödel L, Gärtner U, and Holzer M, "Expression of the cyclin-dependent kinase inhibitor p16 in Alzheimer's disease," <u>NeuroReport</u> , 7: 3047-3049 (1996)
	C3	Burke WJ, McLaughlin JR, Chung HD, Gillespie KN, Grossberg GT, Luque FA, and Zimmerman J, "Occurrence of Cancer in Alzheimer and Elderly Control Patients: An Epidemiologic Necropsy Study," <u>Alzheimer Disease and Associated Disorders</u> , Vol. 8: No. 1, pp. 22-28 (1994)
	C4	Darzynkiewicz Z, "Mammalian cell-cycle analysis," <u>The Cell Cycle – A Practical Approach</u> , Fantes P and Brooks R (eds), Oxford University Press, Oxford, pp 43-68 (1993)
	C5	Davies KJ, "The Broad Spectrum of Responses to Oxidants in Proliferating Cells: A New Paradigm for Oxidative Stress," <u>IUBMB Life</u> , 48: 41-47 (1999)
	C6	Drabkin HA and Erickson P, "Down Syndrome and Leukemia, An Update," <u>Etiology and Pathogenesis of Down Syndrome</u> , pp. 169-176 (1995)
	C7	Eckert A, Hartmann H, Förstl H, and Müller WE, "Alterations of Intracellular Calcium Regulation During Aging and Alzheimer's Disease in Nonneuronal Cells," <u>Life Sciences</u> , Vol. 55, Nos. 25/26, pp. 2019-2029 (1994)
	C8	Fischman HK, Reisberg B, Albu P, Ferris SH, and Rainer JD, "Sister Chromatid Exchanges and Cell Cycle Kinetics in Alzheimer's Disease," <u>Biological Psychiatry</u> , 19: 319-327 (1984)
	C9	Mecocci P, Polidori MC, Ingegni T, Cherubini A, Chionne F, Cecchetti R, and Senin U, "Oxidative damage to DNA in lymphocytes from AD patients," <u>Neurology</u> , 51: 1014-1017 (1998)
	C10	Melaragno MI, Smith MDA, Kormann-Bortolotto MH, and Neto JT, "Lymphocyte Proliferation and Sister Chromatid Exchange in Alzheimer's Disease," <u>Gerontology</u> , 37: 293-298 (1991)



C11	Mosmann T., "Rapid Colorimetric Assay for Cellular Growth and Survival: Application to Proliferation and Cytotoxicity Assays," <u>Journal of Immunological Methods</u> , 65: 55-63 (1983)
C12	Nagy ZS, Esiri MM, and Smith AD, "The Cell Division Cycle and the Pathophysiology of Alzheimer's Disease," <u>Neuroscience</u> , 87: 731-739 (1998)
C13	Payão SL, Smith MdA and Bertolucci PH, "Differential Chromosome Sensitivity to 5-Azacytidine in Alzheimer's Disease," <u>Gerontology</u> , 44: 267-271 (1998)
C14	Schafer AJ and Hawkins JR, "DNA variation and the future of human genetics," <u>Nature Biotechnology</u> , Vol: 16, pp. 33-39 (1998)
C15	Sherr CJ, "Growth Factor-Regulated G ₁ Cyclins," <u>Polyfunctionality of Hemopoietic Regulators: The Metcalf Forum. STEM CELLS</u> , 12 (suppl 1): 47-57 (1994)
C16	Tatebayashi Y, Takeda M, Kashiwagi Y, Okochi M, Kurumadani T, Sekiyama A, Kanayama G, Hariguchi S, and Nishimura T, "Cell-Cycle-Dependent Abnormal Calcium Response in Fibroblasts from Patients with Familial Alzheimer's Disease," <u>Dementia</u> , 6: 9-16 (1995)
C17	Trieb K, Ransmayr G, Sgonc R, Lassmann H, and Grubeck Loebenstein B, "APP Peptides Stimulate Lymphocyte Proliferation in Normals, But Not in Patients With Alzheimer's Disease," <u>Neurobiology of Aging</u> , 17: 541-547 (1996)
C18	Wagner EF, Hleb M, Hanna N, and Sharma S, "A Pivotal Role of Cyclin D3 and Cyclin-Dependent Kinase Inhibitor p27 in the Regulation of IL-2-, IL-4-, or IL-10-Mediated Human B Cell Proliferation," <u>Journal of Immunology</u> , 161: 1123-1131 (1998)
C19	Araga S, Kagimoto H, Funamoto K and Takahashi K "Lymphocyte Proliferation and Subpopulations in Dementia of the Alzheimer Type" (1990) <u>Jpn J Med</u> 29: 572-5
C20	Fong CT and Brodeur GM "Down's Syndrome and Leukemia: Epidemiology, Genetics, Cytogenetics and Mechanisms of Leukemogenesis" (1987) <u>Cancer Genet Cytogenet</u> 28: 55-76
C21	McKhann, G. et al., "Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group* under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease" (1984) <u>Neurology</u> 34: 939-944
C22	Nagy Z, Esiri MM, Hindley NJ, Joachim C, Morris JH, King EM-F, McDonald B, Litchfield S, Barnetson L, Jobst KA and Smith AD "Accuracy of Clinical Operational Diagnostic Criteria for Alzheimer's Disease in Relation to Different Pathological Diagnostic Protocols" (1998) <u>Dementia</u> 9: 219-226

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.